Clinical Trial

An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2024-02-02; most recent amendment 2025-11-18.
Status change: Enrolling by Invitation → Active, Not Recruiting 2025-11-18
Status change: Recruiting → Enrolling by Invitation 2024-08-04
Trial Details
NCT Number NCT06254482
Lead Sponsor Novartis Pharmaceuticals
Conditions Huntington Disease
Enrollment 144 participants
Start Date 2023-08-25
Primary Completion 2029-07-16 (estimated)
Study Completion 2029-07-16 (estimated)
Updated on ClinicalTrials.gov 2025-11-21